Table 2.
Examples of other PARP inhibitors under phase III investigation in the US according to www.ClinicalTrials.gov
| PARP inhibitor | Study | Disease type (ovarian trials highlighted in bold print) | Trial status |
|---|---|---|---|
| Iniparib | Gemcitabine and carboplatin with or without iniparib (PARP1 inhibitor) in subjects with untreated stage IV NSCLC | Stage IV NSCLC, untreated | Completed |
| Phase III, multicenter study of gemcitabine/carboplatin with or without BSI-201 (iniparib) in patients with ER negative, PR negative, HER-2 negative metastatic breast cancer | Triple-negative, metastatic breast cancer | Completed | |
| Talazoparib | Talazoparib vs physician’s choice chemotherapy in advanced or metastatic breast cancer with BRCA mutation | Advanced or metastatic breast cancer BRCAm | Active/not recruiting |
| Veliparib | Randomized-controlled trial of carboplatin/paclitaxel with or without veliparib in HER-2 negative or locally advanced unresectable BRCA- associated breast cancer | Locally advanced breast cancer BRCAm HER-2 negative | Active/not recruiting |
| Veliparib with carboplatin/paclitaxel and continuation maintenance in stage III or IV high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG 3005) | Stage III or stage IV high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer | Active/not recruiting | |
| Randomized, double blind, multi-center study comparing veliparib vs placebo with carboplatin/paclitaxel in previously untreated advanced or metastatic non-small-cell lung cancer (NSCLC) | Stage IV NSCLC, untreated | Active/not recruiting | |
| Veliparib with carboplatin/paclitaxel vs physician’s choice standard chemotherapy in patients receiving their first cytotoxic chemotherapy for metastatic or advanced NSCLC who are current or former smokers | Metastatic or advanced NSCLC current or former smokers | Active/not recruiting | |
| Nirapirib | Nirapirib vs placebo in patients with platinum-sensitive ovarian cancer (NOVA, GOG-3012) | Platinum-sensitive ovarian cancer | Completed |
| A phase III trial of nirapirib vs physician’s choice chemotherapy in HER-2 negative, germline BRCA mutation positive breast cancer (BRAVO) | HER-2 negative breast cancer BRCAm | Active/not recruiting | |
| Nirapirib vs placebo maintenance treatment in patients with advanced ovarian cancer following response on front-line platinum-based chemotherapy (PRIMA) | Advanced ovarian cancer | Active/not recruiting | |
| Olaparib | Olapirib in BRCA mutation pancreatic cancer patients whose disease has not progressed on first-line platinum-based chemotherapy (POLO) | Pancreatic cancer BRCAm | Recruiting |
| Assessment of efficacy/safety of olaparib mono therapy vs physician’s choice chemotherapy in the treatment of metastatic breast cancer in patients with germline BRCA1/2 mutations (OLYMPIAD) | Metastatic breast cancer BRCAm | Active/not recruiting | |
| Cediranib maleate with olapirib or standard chemotherapy in treating patients with recurrent platinum-resistant or refractory ovarian, fallopian tube or primary peritoneal cancer | Ovarian, fallopian tube or primary peritoneal cancer platinum-resistant or refractory | Suspended for scheduled monitoring | |
| Olaparib or cedirinib maleate with olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum- sensitive ovarian, fallopian tube, or primary peritoneal cancer | Ovarian, fallopian tube or primary peritoneal cancer platinum-sensitive | Recruiting | |
| Platine, Avastin, and Olaparib. A double-blind, phase III trial of Olaparib vs placebo in patients with advanced stage IIIB–IV high grade serous or endometrioid ovarian, fallopian ntube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance | Advanced high grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer | Recruiting | |
| Pamiparib | BCB-290 (pamiparib) vs placebo with advanced or inoperable gastric cancer | Advanced or inoperable gastric cancer | Recruiting |
Abbreviations: ER, estrogen receptor; GOG, Gynecologic Oncology Group; HER-2, human epidermal growth factor receptor 2; HRD, homologous recombination deficient; NSCLC, non-small-cell lung cancer; PR, progesterone receptor.